These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 8328203)

  • 1. The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activator.
    Huber K; Beckmann R; Rauscha F; Probst P; Kaindl F; Binder BR
    Z Kardiol; 1993; 82 Suppl 2():195-200. PubMed ID: 8328203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery.
    Paganelli F; Alessi MC; Morange P; Maixent JM; Lévy S; Vague IJ
    Thromb Haemost; 1999 Jul; 82(1):104-8. PubMed ID: 10456462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of cardiac output on peak t-PA plasma levels in patients receiving thrombolytic therapy with recombinant tissue-type plasminogen activator--correlation with patency rate.
    Huber K; Beckmann R; Probst P; Rauscha F; Kaindl F; Binder BR
    Thromb Haemost; 1993 Jan; 69(1):45-9. PubMed ID: 8446938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
    Cruden NL; Graham C; Harding SA; Ludlam CA; Fox KA; Newby DE
    Thromb Res; 2006; 118(2):189-97. PubMed ID: 16055173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-I levels in acute myocardial infarction.
    Yamada S; Yamada R; Ishii A; Ashikawa K; Kawamitsu H; Fujita K
    J Cardiol; 1996 Apr; 27(4):171-8. PubMed ID: 8642503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction.
    Parise P; Hauert J; Iorio A; Callegari P; Agnelli G
    J Lab Clin Med; 1995 Feb; 125(2):212-21. PubMed ID: 7531212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease.
    Pedersen OD; Gram J; Jespersen J
    Thromb Haemost; 1995 May; 73(5):835-40. PubMed ID: 7482412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procoagulant properties of intravenous staphylokinase versus tissue-type plasminogen activator.
    Okada K; Lijnen HR; Moreau H; Vanderschueren S; Collen D
    Thromb Haemost; 1996 Dec; 76(6):857-9. PubMed ID: 8972000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction.
    Sane DC; Stump DC; Topol EJ; Sigmon KN; Kereiakes DJ; George BS; Mantell SJ; Macy E; Collen D; Califf RM
    Thromb Haemost; 1991 Mar; 65(3):275-9. PubMed ID: 1904653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.
    van Griensven JM; Koster RW; Burggraaf J; Huisman LG; Kluft C; Kroon R; Schoemaker RC; Cohen AF
    Clin Pharmacol Ther; 1998 Jan; 63(1):39-47. PubMed ID: 9465840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
    Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
    Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The absence of a procoagulant effect after TNK-t-PA: a comparison with streptokinase and rt-PA].
    De Marco E; Andreotti F; van de Greef W; Quaranta G; Biasucci LM; Kol A; Maseri A; Rebuzzi AG
    Cardiologia; 1998 Nov; 43(11):1209-13. PubMed ID: 9922587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transmyocardial fibrinolytic activity in patients with unstable angina pectoris.
    Daniel WC; Meidell RS; Hillis LD; Lange RA
    Coron Artery Dis; 1996 Jan; 7(1):45-9. PubMed ID: 8773432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Chen LY; Nichols WW; Mattsson C; Teger-Nilson AC; Wallin R; Saldeen TG; Mehta JL
    Cardiovasc Res; 1995 Dec; 30(6):866-74. PubMed ID: 8746200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Platelet activation in the early phases of acute myocardial infarction].
    Salvioni A; Giraldi F; Assanelli E; Lauri G; Grazi M; Pardea S; Marenzi G
    Cardiologia; 1998 Aug; 43(8):825-32. PubMed ID: 9808873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New substances and dosages for thrombolysis in acute myocardial infarct].
    Zeymer U; Neuhaus KL
    Z Kardiol; 1993; 82 Suppl 2():137-41. PubMed ID: 8328192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) and urokinase in acute myocardial infarct: intermediate results of the G.A.U.S. study (German Activator Urokinase Study)].
    Neuhaus KL; Tebbe U; Gottwik M; Weber MA; Feuerer W; Niederer W; Haerer W; Praetorius F; Grosser KD; Huhmann W
    Klin Wochenschr; 1988; 66 Suppl 12():102-8. PubMed ID: 3126339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Von Willebrand factor, plasminogen activator inhibitor-1 and C-reactive protein are markers of thrombolytic efficacy in acute myocardial infarction.
    Andreotti F; Hackett DR; Haider AW; Roncaglioni MC; Davies GJ; Beacham JL; Kluft C; Maseri A
    Thromb Haemost; 1992 Dec; 68(6):678-82. PubMed ID: 1287882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.